Home > > > > > Report Detail

Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Size, Manufacturers, Supply Chain, Sales Channel and Clients, 2022-2028

Publisher Name :
Date: 02-Sep-2022
No. of pages: 108
Inquire Before Buying

Glucagon like peptide-1 (GLP-1) agonists is the agonists of the GLP-1 receptor. This class of drugs is used for the treatment of type 2 diabetes. One of their advantages is over older insulin secretagogues, such as sulfonylureas or meglitinides, and they have a lower risk of causing hypoglycemia.

Highlights

Considering the economic change due to COVID-19 and Russia-Ukraine War Influence, the global Glucagon Like Peptide-1 (GLP-1) Agonists market is projected to reach US$ 21340 million by 2028 from an estimated US$ 10090 million in 2022, at a CAGR of 13.3% during 2023 and 2028.

Market competition is intense. Novo Nordisk, AstraZeneca, Eli Lilly, GSK and Sanofi are the leader of the industry. Novo Nordisk is the top one of this industry by 68% market shares.

United States is the largest consumer of Glucagon like peptide-1 (GLP-1) agonists with the production market share of 35% and the consumption market share of 44%. The second place is Europe, following North America with the production market share of 63% and the consumption market share of 28%.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Glucagon Like Peptide-1 (GLP-1) Agonists, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyse their position in the current marketplace, and make informed business decisions regarding Glucagon Like Peptide-1 (GLP-1) Agonists.

The Glucagon Like Peptide-1 (GLP-1) Agonists market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2021 as the base year, with history and forecast data for the period from 2017 to 2028. This report segments the global Glucagon Like Peptide-1 (GLP-1) Agonists market comprehensively. Regional market sizes, concerning products by types, by application, and by players, are also provided. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Glucagon Like Peptide-1 (GLP-1) Agonists manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, product type, application, and regions.

Key Companies & Market Share Insights

In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2017-2022. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses. Some of the prominent players reviewed in the research report include:

- Novo Nordisk

- AstraZeneca

- Eli Lily

- GSK

- Sanofi

- Bristol-Myers Squibb

- Amylin

Product Type Insights

Global markets are presented by Glucagon Like Peptide-1 (GLP-1) Agonists type, along with growth forecasts through 2028. Estimates on sales and revenue are based on the price in the supply chain at which the Glucagon Like Peptide-1 (GLP-1) Agonists are procured by the manufacturers.

This report has studied every segment and provided the market size using historical data. They have also talked about the growth opportunities that the segment may pose in the future. This study bestows sales and revenue data by type, and during the historical period (2017-2022) and forecast period (2023-2028).

Glucagon Like Peptide-1 (GLP-1) Agonists Segment by Type

- Exenatied

- Liraglutide

- Lixisenatide

- Albiglutide

- Dulaglutide

Application Insights

This report has provided the market size (sales and revenue data) by application, during the historical period (2017-2022) and forecast period (2023-2028).

This report also outlines the market trends of each segment and consumer behaviors impacting the Glucagon Like Peptide-1 (GLP-1) Agonists market and what implications these may have on the industry's future. This report can help to understand the relevant market and consumer trends that are driving the Glucagon Like Peptide-1 (GLP-1) Agonists market.

Glucagon Like Peptide-1 (GLP-1) Agonists Segment by Application

- Hospital

- Pharmacy

- Other

Regional Outlook

This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the revenue and sales data of each region and country for the period 2017-2028.

The market has been segmented into various major geographies, including North America, Europe, Asia-Pacific, South America, Middle East & Africa. Detailed analysis of major countries such as the USA, Germany, the U.K., Italy, France, China, Japan, South Korea, Southeast Asia, and India will be covered within the regional segment. For market estimates, data are going to be provided for 2021 because of the base year, with estimates for 2022 and forecast revenue for 2028.

- North America

- - United States

- - Canada

- Europe

- - Germany

- - France

- - U.K.

- - Italy

- - Russia

- - Nordic Countries

- - Benelux

- - Rest of Europe

- Asia-Pacific

- - China

- - Japan

- - South Korea

- - India

- - Southeast Asia

- - Australia

- - Rest of Asia-Pacific

- Latin America

- - Mexico

- - Brazil

- - Argentina

- - Rest of Latin America

- Middle East & Africa

- - Turkey

- - Saudi Arabia

- - UAE

- - Rest of Middle East & Africa

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

COVID-19 and Russia-Ukraine War Influence Analysis

The readers in the section will understand how the Glucagon Like Peptide-1 (GLP-1) Agonists market scenario changed across the globe during the pandemic, post-pandemic and Russia-Ukraine War. The study is done keeping in view the changes in aspects such as demand, consumption, transportation, consumer behavior, supply chain management, export and import, and production. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.

Reasons to Buy This Report

This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Glucagon Like Peptide-1 (GLP-1) Agonists market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

This report will help stakeholders to understand the global industry status and trends of Glucagon Like Peptide-1 (GLP-1) Agonists and provides them with information on key market drivers, restraints, challenges, and opportunities.

This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

This report stays updated with novel technology integration, features, and the latest developments in the market

This report helps stakeholders to understand the COVID-19 and Russia-Ukraine War Influence on the Glucagon Like Peptide-1 (GLP-1) Agonists industry.

This report helps stakeholders to gain insights into which regions to target globally

This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Glucagon Like Peptide-1 (GLP-1) Agonists

This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution

Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Size, Manufacturers, Supply Chain, Sales Channel and Clients, 2022-2028

Table of Contents
1 Study Coverage
1.1 Glucagon Like Peptide-1 (GLP-1) Agonists Product Introduction
1.2 Market by Type
1.2.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Size Growth Rate by Type (2017 VS 2021 VS 2028)
1.2.2 Exenatied
1.2.3 Liraglutide
1.2.4 Lixisenatide
1.2.5 Albiglutide
1.2.6 Dulaglutide
1.3 Market by Application
1.3.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Size Growth Rate by Application (2017 VS 2021 VS 2028)
1.3.2 Hospital
1.3.3 Pharmacy
1.3.4 Other
1.4 Study Objectives
1.5 Years Considered
2 Executive Summary
2.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Size Estimates and Forecasts
2.1.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue 2017-2028
2.1.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales 2017-2028
2.2 Glucagon Like Peptide-1 (GLP-1) Agonists Market Size by Region: 2022 Versus 2028
2.3 Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Region (2017-2028)
2.3.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Region: 2017-2022
2.3.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Forecast by Region (2023-2028)
2.3.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Region (2017-2028)
2.4 Glucagon Like Peptide-1 (GLP-1) Agonists Market Estimates and Projections by Region (2023-2028)
2.4.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Region: 2017-2022
2.4.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Forecast by Region (2023-2028)
2.4.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Region (2017-2028)
3 Global Glucagon Like Peptide-1 (GLP-1) Agonists by Manufacturers
3.1 Global Top Glucagon Like Peptide-1 (GLP-1) Agonists Manufacturers by Sales
3.1.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Manufacturer (2017-2022)
3.1.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Manufacturer (2017-2022)
3.2 Global Top Glucagon Like Peptide-1 (GLP-1) Agonists Manufacturers by Revenue
3.2.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Manufacturer (2017-2022)
3.2.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Share by Manufacturer (2017-2022)
3.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Price by Manufacturer (2017-2022)
3.4 Competitive Landscape
3.4.1 Key Glucagon Like Peptide-1 (GLP-1) Agonists Manufacturers Covered: Ranking by Revenue
3.4.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Concentration Ratio (CR5 and HHI) & (2017-2022)
3.4.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.5 Global Glucagon Like Peptide-1 (GLP-1) Agonists Manufacturing Base Distribution, Product Type
3.5.1 Glucagon Like Peptide-1 (GLP-1) Agonists Manufacturers Manufacturing Base Distribution, Headquarters
3.5.2 Manufacturers Glucagon Like Peptide-1 (GLP-1) Agonists Product Type
3.5.3 Date of International Manufacturers Enter into Glucagon Like Peptide-1 (GLP-1) Agonists Market
3.6 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Company Profiles
4.1 Novo Nordisk
4.1.1 Novo Nordisk Corporation Information
4.1.2 Novo Nordisk Description, Business Overview
4.1.3 Novo Nordisk Glucagon Like Peptide-1 (GLP-1) Agonists Products Offered
4.1.4 Novo Nordisk Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Revenue and Gross Margin (2017-2022)
4.1.5 Novo Nordisk Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Product in 2021
4.1.6 Novo Nordisk Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Application in 2021
4.1.7 Novo Nordisk Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Geographic Area in 2021
4.1.8 Novo Nordisk Recent Developments
4.2 AstraZeneca
4.2.1 AstraZeneca Corporation Information
4.2.2 AstraZeneca Description, Business Overview
4.2.3 AstraZeneca Glucagon Like Peptide-1 (GLP-1) Agonists Products Offered
4.2.4 AstraZeneca Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Revenue and Gross Margin (2017-2022)
4.2.5 AstraZeneca Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Product in 2021
4.2.6 AstraZeneca Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Application in 2021
4.2.7 AstraZeneca Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Geographic Area in 2021
4.2.8 AstraZeneca Recent Developments
4.3 Eli Lily
4.3.1 Eli Lily Corporation Information
4.3.2 Eli Lily Description, Business Overview
4.3.3 Eli Lily Glucagon Like Peptide-1 (GLP-1) Agonists Products Offered
4.3.4 Eli Lily Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Revenue and Gross Margin (2017-2022)
4.3.5 Eli Lily Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Product in 2021
4.3.6 Eli Lily Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Application in 2021
4.3.7 Eli Lily Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Geographic Area in 2021
4.3.8 Eli Lily Recent Developments
4.4 GSK
4.4.1 GSK Corporation Information
4.4.2 GSK Description, Business Overview
4.4.3 GSK Glucagon Like Peptide-1 (GLP-1) Agonists Products Offered
4.4.4 GSK Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Revenue and Gross Margin (2017-2022)
4.4.5 GSK Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Product in 2021
4.4.6 GSK Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Application in 2021
4.4.7 GSK Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Geographic Area in 2021
4.4.8 GSK Recent Developments
4.5 Sanofi
4.5.1 Sanofi Corporation Information
4.5.2 Sanofi Description, Business Overview
4.5.3 Sanofi Glucagon Like Peptide-1 (GLP-1) Agonists Products Offered
4.5.4 Sanofi Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Revenue and Gross Margin (2017-2022)
4.5.5 Sanofi Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Product in 2021
4.5.6 Sanofi Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Application in 2021
4.5.7 Sanofi Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Geographic Area in 2021
4.5.8 Sanofi Recent Developments
4.6 Bristol-Myers Squibb
4.6.1 Bristol-Myers Squibb Corporation Information
4.6.2 Bristol-Myers Squibb Description, Business Overview
4.6.3 Bristol-Myers Squibb Glucagon Like Peptide-1 (GLP-1) Agonists Products Offered
4.6.4 Bristol-Myers Squibb Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Revenue and Gross Margin (2017-2022)
4.6.5 Bristol-Myers Squibb Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Product in 2021
4.6.6 Bristol-Myers Squibb Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Application in 2021
4.6.7 Bristol-Myers Squibb Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Geographic Area in 2021
4.6.8 Bristol-Myers Squibb Recent Development
4.7 Amylin
4.7.1 Amylin Corporation Information
4.7.2 Amylin Description, Business Overview
4.7.3 Amylin Glucagon Like Peptide-1 (GLP-1) Agonists Products Offered
4.7.4 Amylin Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Revenue and Gross Margin (2017-2022)
4.7.5 Amylin Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Product in 2021
4.7.6 Amylin Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Application in 2021
4.7.7 Amylin Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Geographic Area in 2021
4.7.8 Amylin Recent Development
5 Breakdown Data by Type
5.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Type (2017-2028)
5.1.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Type (2017-2022)
5.1.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Forecast by Type (2023-2028)
5.1.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Type (2017-2028)
5.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Forecast by Type (2017-2028)
5.2.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Type (2017-2022)
5.2.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Forecast by Type (2023-2028)
5.2.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Type (2017-2028)
5.3 Glucagon Like Peptide-1 (GLP-1) Agonists Average Selling Price (ASP) by Type (2017-2028)
6 Breakdown Data by Application
6.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Application (2017-2028)
6.1.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Application (2017-2022)
6.1.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Forecast by Application (2023-2028)
6.1.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Application (2017-2028)
6.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Forecast by Application (2017-2028)
6.2.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Application (2017-2022)
6.2.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Forecast by Application (2023-2028)
6.2.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Application (2017-2028)
6.3 Glucagon Like Peptide-1 (GLP-1) Agonists Average Selling Price (ASP) by Application (2017-2028)
7 North America
7.1 North America Glucagon Like Peptide-1 (GLP-1) Agonists Market Size YoY Growth 2017-2028
7.2 North America Glucagon Like Peptide-1 (GLP-1) Agonists Market Facts & Figures by Country
7.2.1 North America Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Country (2017-2028)
7.2.2 North America Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Country (2017-2028)
7.3 North America Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Type
7.4 North America Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Application
8 Asia-Pacific
8.1 Asia-Pacific Glucagon Like Peptide-1 (GLP-1) Agonists Market Size YoY Growth 2017-2028
8.2 Asia-Pacific Glucagon Like Peptide-1 (GLP-1) Agonists Market Facts & Figures by Region
8.2.1 Asia-Pacific Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Region (2017-2028)
8.2.2 Asia-Pacific Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Region (2017-2028)
8.3 Asia-Pacific Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Type
8.4 Asia-Pacific Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Application
9 Europe
9.1 Europe Glucagon Like Peptide-1 (GLP-1) Agonists Market Size YoY Growth 2017-2028
9.2 Europe Glucagon Like Peptide-1 (GLP-1) Agonists Market Facts & Figures by Country
9.2.1 Europe Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Country (2017-2028)
9.2.2 Europe Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Country (2017-2028)
9.3 Europe Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Type
9.4 Europe Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Application
10 Latin America
10.1 Latin America Glucagon Like Peptide-1 (GLP-1) Agonists Market Size YoY Growth 2017-2028
10.2 Latin America Glucagon Like Peptide-1 (GLP-1) Agonists Market Facts & Figures by Country
10.2.1 Latin America Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Country (2017-2028)
10.2.2 Latin America Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Country (2017-2028)
10.3 Latin America Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Type
10.4 Latin America Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Application
11 Middle East and Africa
11.1 Middle East and Africa Glucagon Like Peptide-1 (GLP-1) Agonists Market Size YoY Growth 2017-2028
11.2 Middle East and Africa Glucagon Like Peptide-1 (GLP-1) Agonists Market Facts & Figures by Country
11.2.1 Middle East and Africa Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Country (2017-2028)
11.2.2 Middle East and Africa Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Country (2017-2028)
11.3 Middle East and Africa Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Type
11.4 Middle East and Africa Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Application
12 Supply Chain and Sales Channel Analysis
12.1 Glucagon Like Peptide-1 (GLP-1) Agonists Supply Chain Analysis
12.2 Glucagon Like Peptide-1 (GLP-1) Agonists Key Raw Materials and Upstream Suppliers
12.3 Glucagon Like Peptide-1 (GLP-1) Agonists Clients Analysis
12.4 Glucagon Like Peptide-1 (GLP-1) Agonists Sales Channel and Sales Model Analysis
12.4.1 Glucagon Like Peptide-1 (GLP-1) Agonists Distribution Channel Analysis: Indirect Sales VS Direct Sales
12.4.2 Glucagon Like Peptide-1 (GLP-1) Agonists Distribution Channel Analysis: Online Sales VS Offline Sales
12.4.3 Glucagon Like Peptide-1 (GLP-1) Agonists Distributors
13 Market Dynamics
13.1 Glucagon Like Peptide-1 (GLP-1) Agonists Industry Trends
13.2 Glucagon Like Peptide-1 (GLP-1) Agonists Market Drivers
13.3 Glucagon Like Peptide-1 (GLP-1) Agonists Market Challenges
13.4 Glucagon Like Peptide-1 (GLP-1) Agonists Market Restraints
13.5 Porter's Five Forces Analysis
14 Research Findings and Conclusion
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer
List of Tables
Table 1. Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Size Growth Rate by Type (US$ Million): 2017 VS 2021 VS 2028
Table 2. Major Manufacturers of Exenatied
Table 3. Major Manufacturers of Liraglutide
Table 4. Major Manufacturers of Lixisenatide
Table 5. Major Manufacturers of Albiglutide
Table 6. Major Manufacturers of Dulaglutide
Table 7. Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Size Growth by Application (US$ Million): 2017 VS 2021 VS 2028
Table 8. Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Size by Region (US$ Million): 2021 VS 2022 VS 2028
Table 9. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Region (2017-2022) & (K Units)
Table 10. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Forecast by Region (2023-2028) & (K Units)
Table 11. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Region (2017-2022) & (US$ Million)
Table 12. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Forecast by Region (2023-2028) & (US$ Million)
Table 13. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Manufacturer (2017-2022) & (K Units)
Table 14. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Share by Manufacturer (2017-2022)
Table 15. Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Manufacturer (2017-2022) & (US$ Million)
Table 16. Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Share by Manufacturer (2017-2022)
Table 17. Key Manufacturers Glucagon Like Peptide-1 (GLP-1) Agonists Price (2017-2022) & (USD/Unit)
Table 18. Ranking of Global Top Glucagon Like Peptide-1 (GLP-1) Agonists Manufacturers by Revenue (US$ Million) in 2021
Table 19. Global Glucagon Like Peptide-1 (GLP-1) Agonists Manufacturers Market Concentration Ratio (CR5 and HHI) & (2017-2022)
Table 20. Global Glucagon Like Peptide-1 (GLP-1) Agonists by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Glucagon Like Peptide-1 (GLP-1) Agonists as of 2021)
Table 21. Glucagon Like Peptide-1 (GLP-1) Agonists Manufacturers Manufacturing Base Distribution and Headquarters
Table 22. Manufacturers Glucagon Like Peptide-1 (GLP-1) Agonists Product Type
Table 23. Date of International Manufacturers Enter into Glucagon Like Peptide-1 (GLP-1) Agonists Market
Table 24. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 25. Novo Nordisk Corporation Information
Table 26. Novo Nordisk Description and Business Overview
Table 27. Novo Nordisk Glucagon Like Peptide-1 (GLP-1) Agonists Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 28. Novo Nordisk Glucagon Like Peptide-1 (GLP-1) Agonists Product
Table 29. Novo Nordisk Glucagon Like Peptide-1 (GLP-1) Agonists Sales Proportion of Glucagon Like Peptide-1 (GLP-1) Agonists by Product in 2021
Table 30. Novo Nordisk Glucagon Like Peptide-1 (GLP-1) Agonists Sales Proportion of Glucagon Like Peptide-1 (GLP-1) Agonists by Application in 2021
Table 31. Novo Nordisk Glucagon Like Peptide-1 (GLP-1) Agonists Sales Proportion of Glucagon Like Peptide-1 (GLP-1) Agonists by Geographic Area in 2021
Table 32. Novo Nordisk Recent Development
Table 33. AstraZeneca Corporation Information
Table 34. AstraZeneca Description and Business Overview
Table 35. AstraZeneca Glucagon Like Peptide-1 (GLP-1) Agonists Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 36. AstraZeneca Glucagon Like Peptide-1 (GLP-1) Agonists Product
Table 37. AstraZeneca Glucagon Like Peptide-1 (GLP-1) Agonists Sales Proportion of Glucagon Like Peptide-1 (GLP-1) Agonists by Product in 2021
Table 38. AstraZeneca Glucagon Like Peptide-1 (GLP-1) Agonists Sales Proportion of Glucagon Like Peptide-1 (GLP-1) Agonists by Application in 2021
Table 39. AstraZeneca Glucagon Like Peptide-1 (GLP-1) Agonists Sales Proportion of Glucagon Like Peptide-1 (GLP-1) Agonists by Geographic Area in 2021
Table 40. AstraZeneca Recent Development
Table 41. Eli Lily Corporation Information
Table 42. Eli Lily Description and Business Overview
Table 43. Eli Lily Glucagon Like Peptide-1 (GLP-1) Agonists Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 44. Eli Lily Glucagon Like Peptide-1 (GLP-1) Agonists Product
Table 45. Eli Lily Glucagon Like Peptide-1 (GLP-1) Agonists Sales Proportion of Glucagon Like Peptide-1 (GLP-1) Agonists by Product in 2021
Table 46. Eli Lily Glucagon Like Peptide-1 (GLP-1) Agonists Sales Proportion of Glucagon Like Peptide-1 (GLP-1) Agonists by Application in 2021
Table 47. Eli Lily Glucagon Like Peptide-1 (GLP-1) Agonists Sales Proportion of Glucagon Like Peptide-1 (GLP-1) Agonists by Geographic Area in 2021
Table 48. Eli Lily Recent Development
Table 49. GSK Corporation Information
Table 50. GSK Description and Business Overview
Table 51. GSK Glucagon Like Peptide-1 (GLP-1) Agonists Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 52. GSK Glucagon Like Peptide-1 (GLP-1) Agonists Product
Table 53. GSK Glucagon Like Peptide-1 (GLP-1) Agonists Sales Proportion of Glucagon Like Peptide-1 (GLP-1) Agonists by Product in 2021
Table 54. GSK Glucagon Like Peptide-1 (GLP-1) Agonists Sales Proportion of Glucagon Like Peptide-1 (GLP-1) Agonists by Application in 2021
Table 55. GSK Glucagon Like Peptide-1 (GLP-1) Agonists Sales Proportion of Glucagon Like Peptide-1 (GLP-1) Agonists by Geographic Area in 2021
Table 56. GSK Recent Development
Table 57. Sanofi Corporation Information
Table 58. Sanofi Description and Business Overview
Table 59. Sanofi Glucagon Like Peptide-1 (GLP-1) Agonists Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 60. Sanofi Glucagon Like Peptide-1 (GLP-1) Agonists Product
Table 61. Sanofi Glucagon Like Peptide-1 (GLP-1) Agonists Sales Proportion of Glucagon Like Peptide-1 (GLP-1) Agonists by Product in 2021
Table 62. Sanofi Glucagon Like Peptide-1 (GLP-1) Agonists Sales Proportion of Glucagon Like Peptide-1 (GLP-1) Agonists by Application in 2021
Table 63. Sanofi Glucagon Like Peptide-1 (GLP-1) Agonists Sales Proportion of Glucagon Like Peptide-1 (GLP-1) Agonists by Geographic Area in 2021
Table 64. Sanofi Recent Development
Table 65. Bristol-Myers Squibb Corporation Information
Table 66. Bristol-Myers Squibb Description and Business Overview
Table 67. Bristol-Myers Squibb Glucagon Like Peptide-1 (GLP-1) Agonists Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 68. Bristol-Myers Squibb Glucagon Like Peptide-1 (GLP-1) Agonists Product
Table 69. Bristol-Myers Squibb Glucagon Like Peptide-1 (GLP-1) Agonists Sales Proportion of Glucagon Like Peptide-1 (GLP-1) Agonists by Product in 2021
Table 70. Bristol-Myers Squibb Glucagon Like Peptide-1 (GLP-1) Agonists Sales Proportion of Glucagon Like Peptide-1 (GLP-1) Agonists by Application in 2021
Table 71. Bristol-Myers Squibb Glucagon Like Peptide-1 (GLP-1) Agonists Sales Proportion of Glucagon Like Peptide-1 (GLP-1) Agonists by Geographic Area in 2021
Table 72. Amylin Corporation Information
Table 73. Amylin Description and Business Overview
Table 74. Amylin Glucagon Like Peptide-1 (GLP-1) Agonists Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 75. Amylin Glucagon Like Peptide-1 (GLP-1) Agonists Product
Table 76. Amylin Glucagon Like Peptide-1 (GLP-1) Agonists Sales Proportion of Glucagon Like Peptide-1 (GLP-1) Agonists by Product in 2021
Table 77. Amylin Glucagon Like Peptide-1 (GLP-1) Agonists Sales Proportion of Glucagon Like Peptide-1 (GLP-1) Agonists by Application in 2021
Table 78. Amylin Glucagon Like Peptide-1 (GLP-1) Agonists Sales Proportion of Glucagon Like Peptide-1 (GLP-1) Agonists by Geographic Area in 2021
Table 79. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Type (2017-2022) & (K Units)
Table 80. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Forecast by Type (2023-2028) & (K Units)
Table 81. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Type (2017-2022) & (US$ Million)
Table 82. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Forecast by Type (2023-2028) & (US$ Million)
Table 83. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Application (2017-2022) & (K Units)
Table 84. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Forecast by Application (2023-2028) & (K Units)
Table 85. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Application (2017-2022) & (US$ Million)
Table 86. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Forecast by Application (2023-2028) & (US$ Million)
Table 87. North America Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Country (2017-2022) & (K Units)
Table 88. North America Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Country (2023-2028) & (K Units)
Table 89. North America Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Country (2017-2022) & (US$ Million)
Table 90. North America Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Country (2023-2028) & (US$ Million)
Table 91. North America Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Type (2017-2022) & (K Units)
Table 92. North America Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Application (2017-2022) & (K Units)
Table 93. Asia-Pacific Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Region (2017-2022) & (K Units)
Table 94. Asia-Pacific Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Region (2023-2028) & (K Units)
Table 95. Asia-Pacific Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Region (2017-2028) & (US$ Million)
Table 96. Asia-Pacific Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Region (2023-2028) & (US$ Million)
Table 97. Asia-Pacific Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Type (2017-2022) & (K Units)
Table 98. Asia-Pacific Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Application (2017-2022) & (K Units)
Table 99. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Country (2017-2022) & (K Units)
Table 100. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Country (2023-2028) & (K Units)
Table 101. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Country (2017-2022) & (US$ Million)
Table 102. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Country (2023-2028) & (US$ Million)
Table 103. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Type (2017-2022) & (K Units)
Table 104. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Application (2017-2022) & (K Units)
Table 105. Latin America Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Country (2017-2022) & (K Units)
Table 106. Latin America Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Country (2023-2028) & (K Units)
Table 107. Latin America Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Country (2017-2022) & (US$ Million)
Table 108. Latin America Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Country (2023-2028) & (US$ Million)
Table 109. Latin America Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Type (2017-2022) & (K Units)
Table 110. Latin America Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Application (2017-2022) & (K Units)
Table 111. Middle East and Africa Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Country (2017-2022) & (K Units)
Table 112. Middle East and Africa Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Country (2023-2028) & (K Units)
Table 113. Middle East and Africa Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Country (2017-2022) & (US$ Million)
Table 114. Middle East and Africa Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Country (2023-2028) & (US$ Million)
Table 115. Middle East and Africa Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Type (2017-2022) & (K Units)
Table 116. Middle East and Africa Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Application (2017-2022) & (K Units)
Table 117. Glucagon Like Peptide-1 (GLP-1) Agonists Key Raw Materials, Industry Status and Trend
Table 118. Glucagon Like Peptide-1 (GLP-1) Agonists Key Raw Materials and Upstream Suppliers
Table 119. Glucagon Like Peptide-1 (GLP-1) Agonists Clients Status and Trend
Table 120. Glucagon Like Peptide-1 (GLP-1) Agonists Typical Clients
Table 121. Glucagon Like Peptide-1 (GLP-1) Agonists Distributors
Table 122. Glucagon Like Peptide-1 (GLP-1) Agonists Market Trends
Table 123. Glucagon Like Peptide-1 (GLP-1) Agonists Market Drivers
Table 124. Glucagon Like Peptide-1 (GLP-1) Agonists Market Challenges
Table 125. Glucagon Like Peptide-1 (GLP-1) Agonists Market Restraints
Table 126. Research Programs/Design for This Report
Table 127. Key Data Information from Secondary Sources
Table 128. Key Data Information from Primary Sources
List of Figures
Figure 1. Glucagon Like Peptide-1 (GLP-1) Agonists Product Picture
Figure 2. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Type in 2021 & 2028
Figure 3. Exenatied Product Picture
Figure 4. Liraglutide Product Picture
Figure 5. Lixisenatide Product Picture
Figure 6. Albiglutide Product Picture
Figure 7. Dulaglutide Product Picture
Figure 8. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Application in 2021 & 2028
Figure 9. Hospital Examples
Figure 10. Pharmacy Examples
Figure 11. Other Examples
Figure 12. Glucagon Like Peptide-1 (GLP-1) Agonists Report Years Considered
Figure 13. Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Size, (US$ Million), 2017 VS 2021 VS 2028
Figure 14. Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Size 2017-2028 (US$ Million)
Figure 15. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales 2017-2028 (K Units)
Figure 16. Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Size Market Share by Region: 2022 Versus 2028
Figure 17. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share Forecast by Region (2017-2028)
Figure 18. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Region (2017-2028)
Figure 19. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Share by Manufacturer in 2021
Figure 20. Glucagon Like Peptide-1 (GLP-1) Agonists Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2017 VS 2021
Figure 21. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share Forecast by Type (2017-2028)
Figure 22. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share Forecast by Type (2017-2028)
Figure 23. Glucagon Like Peptide-1 (GLP-1) Agonists Average Selling Price (ASP) by Type (2017-2022) & (USD/Unit)
Figure 24. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share Forecast by Application (2017-2028)
Figure 25. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share Forecast by Application (2017-2028)
Figure 26. Glucagon Like Peptide-1 (GLP-1) Agonists Average Selling Price (ASP) by Application (2017-2022) & (USD/Unit)
Figure 27. North America Glucagon Like Peptide-1 (GLP-1) Agonists Revenue 2017-2028 (US$ Million)
Figure 28. North America Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Type (2017-2022)
Figure 29. North America Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Application (2017-2022)
Figure 30. Asia-Pacific Glucagon Like Peptide-1 (GLP-1) Agonists Revenue 2017-2028 (US$ Million)
Figure 31. Asia-Pacific Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Region (2017-2028)
Figure 32. Asia-Pacific Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Region (2017-2028)
Figure 33. Asia-Pacific Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Type (2017-2022)
Figure 34. Asia-Pacific Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Application (2017-2022)
Figure 35. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Growth Rate 2017-2028 (US$ Million)
Figure 36. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Country (2017-2028)
Figure 37. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Country (2017-2028)
Figure 38. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Type (2017-2022)
Figure 39. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Application (2017-2022)
Figure 40. Latin America Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Growth Rate 2017-2028 (US$ Million)
Figure 41. Latin America Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Country (2017-2028)
Figure 42. Latin America Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Country (2017-2022)
Figure 43. Latin America Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Type (2017-2022)
Figure 44. Latin America Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Application (2017-2022)
Figure 45. Middle East and Africa Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Growth Rate 2017-2028 (US$ Million)
Figure 46. Middle East and Africa Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Country (2017-2028)
Figure 47. Middle East and Africa Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Country (2017-2028)
Figure 48. Middle East and Africa Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Type (2017-2022)
Figure 49. Middle East and Africa Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Application (2017-2022)
Figure 50. Glucagon Like Peptide-1 (GLP-1) Agonists Supply Chain (Upstream and Downstream Market)
Figure 51. Global Production Market Share of Glucagon Like Peptide-1 (GLP-1) Agonists Raw Materials by Region in 2021
Figure 52. Glucagon Like Peptide-1 (GLP-1) Agonists Distribution Channels
Figure 53. Global Glucagon Like Peptide-1 (GLP-1) Agonists Percentage 2017-2028: Indirect Sales VS Direct Sales
Figure 54. Global Glucagon Like Peptide-1 (GLP-1) Agonists Percentage 2017-2028: Online Sales VS Offline Sales
Figure 55. Bottom-up and Top-down Approaches for This Report
Figure 56. Data Trian
  • Global Metformin Hydrochloride Market Research Report 2024
    Published: 08-Jan-2024        Price: US 2900 Onwards        Pages: 104
    Metformin hydrochloride is The raw material of finished product metformin hydrochloride drugs. That is The API metformin hydrochloride. Metformin Hydrochloride finished product is an oral antihyperglycemic drug used in The management of type 2-diabetes. Metformin hydrochloride (N, N-dimethylimidodicarbonimidic diamide hydrochloride) is not chemically or pharmacologically related to any other classes of oral antihyperglycemic agents. Metformin hydrochloride is a white to off-white crystall......
  • Global Antidiabetic Sulphonylureas Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
    Published: 04-Jan-2024        Price: US 3380 Onwards        Pages: 112
    Market Overview of Global Antidiabetic Sulphonylureas market: According to our latest research, the global Antidiabetic Sulphonylureas market looks promising in the next 5 years. As of 2022, the global Antidiabetic Sulphonylureas market was estimated at USD XX million, and it's anticipated to reach USD XX million in 2028, with a CAGR of XX% during the forecast years. This report covers a research time span from 2018 to 2028, and presents a deep and comprehensive analysis of t......
  • Global Insulin Market Growth 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 101
    According to our LPI (LP Information) latest study, the global Insulin market size was valued at US$ million in 2023. With growing demand in downstream market, the Insulin is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during review period. The research report highlights the growth potential of the global Insulin market. Insulin are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply chain optimization......
  • Global Insulin API Market Growth 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 116
    According to our LPI (LP Information) latest study, the global Insulin API market size was valued at US$ 1707.6 million in 2023. With growing demand in downstream market, the Insulin API is forecast to a readjusted size of US$ 2101.4 million by 2030 with a CAGR of 3.0% during review period. The research report highlights the growth potential of the global Insulin API market. Insulin API are expected to show stable growth in the future market. However, product differentiation, reducing co......
  • Global Glucagon Market Growth 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 101
    According to our LPI (LP Information) latest study, the global Glucagon market size was valued at US$ 543.9 million in 2023. With growing demand in downstream market, the Glucagon is forecast to a readjusted size of US$ 835.7 million by 2030 with a CAGR of 6.3% during review period. The research report highlights the growth potential of the global Glucagon market. Glucagon are expected to show stable growth in the future market. However, product differentiation, reducing costs, and suppl......
  • Global Acarbose Market Growth 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 95
    According to our LPI (LP Information) latest study, the global Acarbose market size was valued at US$ 135.8 million in 2023. With growing demand in downstream market, the Acarbose is forecast to a readjusted size of US$ 165.9 million by 2030 with a CAGR of 2.9% during review period. The research report highlights the growth potential of the global Acarbose market. Acarbose are expected to show stable growth in the future market. However, product differentiation, reducing costs, and suppl......
  • Global Insulin Glargine Market Growth 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 77
    According to our LPI (LP Information) latest study, the global Insulin Glargine market size was valued at US$ 6562.1 million in 2023. With growing demand in downstream market, the Insulin Glargine is forecast to a readjusted size of US$ 8722.5 million by 2030 with a CAGR of 4.1% during review period. The research report highlights the growth potential of the global Insulin Glargine market. Insulin Glargine are expected to show stable growth in the future market. However, product differen......
  • Global Liraglutide Market Growth 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 103
    According to our LPI (LP Information) latest study, the global Liraglutide market size was valued at US$ million in 2023. With growing demand in downstream market, the Liraglutide is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during review period. The research report highlights the growth potential of the global Liraglutide market. Liraglutide are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply ch......
  • Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Growth 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 96
    According to our LPI (LP Information) latest study, the global Glucagon Like Peptide-1 (GLP-1) Agonists market size was valued at US$ 8624.4 million in 2023. With growing demand in downstream market, the Glucagon Like Peptide-1 (GLP-1) Agonists is forecast to a readjusted size of US$ 21310 million by 2030 with a CAGR of 13.8% during review period. The research report highlights the growth potential of the global Glucagon Like Peptide-1 (GLP-1) Agonists market. Glucagon Like Peptide-1 (GL......
    • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs